Latest news with #Jnana
Business Wire
13 hours ago
- Business
- Business Wire
Atalanta Therapeutics Announces Leadership Transitions
BOSTON--(BUSINESS WIRE)-- Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of intractable neurological diseases, announced today that Joanne Kotz has been named Chief Executive Officer and a member of the Board of Directors, succeeding Alicia Secor, who has stepped down as part of a planned transition to pursue other opportunities. The company also announced the appointment of Douglas Pagán as Chief Financial Officer & Chief Operating Officer, succeeding Jeffrey Young. Additionally, Bob D. Brown, an industry veteran with extensive RNAi drug discovery and development experience, has joined the company's Scientific Advisory Board to advise as the company advances its innovative pipeline into the clinic. "I want to thank Alicia for her extraordinary leadership of the company from formation to the cusp of entry into the clinic, as well as her continued role as an advisor through this transition,' said Dr. Stephen Knight, President and Senior Managing Partner of F-Prime and a member of the Atalanta Board of Directors. 'We are delighted to have Joanne lead Atalanta's next stage. Joanne is an accomplished leader who has demonstrated the ability to advance innovative platforms and pipelines through the transition to clinical stage, and has optimized company value creation through strong financings, partnerships and strategic transactions.' 'I'm thrilled to be joining Atalanta, which is pioneering the effort to bring RNAi therapies to patients living with devastating neurological diseases,' said Dr. Kotz. 'I am passionately committed to Atalanta's mission to deliver life-transforming therapies to patients and look forward to working with the team to transition our first programs into the clinic as we work to realize the full therapeutic potential of Atalanta's innovative di-siRNA platform.' 'Over the past six years we've made incredible scientific progress at Atalanta. I'm proud of all that we've been able to accomplish together and thank the Board and team for their support and dedication to our mission,' said Ms. Secor. 'The transition from research to clinical stage is a critical time for any biotech, and Joanne's leadership and experience is ideally suited to guide Atalanta's continued progress towards our mission of delivering RNAi medicines to patients living with severe neurological diseases.' Dr. Kotz brings to Atalanta extensive executive experience, including most recently as cofounder and CEO of Jnana Therapeutics. She led the company from an early discovery platform stage through the transition to clinical stage. Jnana was acquired by Otsuka Pharmaceutical in 2024 for ~$1 billion following the demonstration of positive clinical proof of concept for the company's lead rare disease program. Prior to Jnana, Dr. Kotz held leadership roles at FBRI, F-Prime Capital's initiative to enable therapeutic breakthroughs in Alzheimer's disease and related brain disorders, and at the Broad Institute. She is a member of the Board of Directors of the Chordoma Foundation. Dr. Kotz received her Ph.D. in chemistry from the University of California, Berkeley and a B.S. in chemistry from the University of Florida. She conducted postdoctoral research at Genentech and at the Necker Children's Hospital in Paris. Mr. Pagán brings to Atalanta more than two decades of experience in finance, investor relations, and capital formation across both public and venture-backed biopharmaceutical companies. Prior to joining Atalanta, he served as Chief Financial Officer and Chief Operating Officer at Jnana Therapeutics, where he was instrumental in securing the company's $107 million Series C financing heading into the clinic, and the subsequent ~$1 billion acquisition by Otsuka Pharmaceutical. Prior to Jnana, Mr. Pagán was Chief Financial Officer at the RNAi company Dicerna Pharmaceuticals, where he oversaw the 2021 sale of the company to Novo Nordisk for $3.3 billion. He has previously held leadership roles at Acceleron and Biogen and has served on the Board of Directors of the biotech companies Ziopharm Oncology and Timberlyne Therapeutics. Mr. Pagán holds an MBA from Columbia Business School and a BSE in chemical engineering from Princeton University. Dr. Brown brings more than 30 years of experience in RNAi and oligonucleotide research and development, including from discovery through drug approval and across a wide range of clinical indications and regulatory jurisdictions. Most recently, Dr. Brown served as Chief Scientific Officer and Executive Vice President of R&D at Dicerna Pharmaceuticals, an RNAi-focused therapeutics company that was acquired by Novo Nordisk. At Novo, he served as President and Head of the Dicerna Transformation Research Unit and SVP. Prior to Dicerna, Dr. Brown held various R&D leadership positions at Genta, a clinical-stage antisense oligonucleotide therapeutics company, and previously was a co-founder of Oasis Biosciences, which was acquired by Gen-Probe. Dr. Brown earned a Ph.D. in molecular biology from the University of California, Berkeley and B.S. degrees in chemistry and biology from the University of Washington, Seattle. About Atalanta Therapeutics Atalanta Therapeutics is a biotechnology company developing treatments for intractable diseases of the central nervous system using RNA interference. Atalanta's unique platform of divalent small interfering RNA (di-siRNA) is designed to enable durable, selective gene silencing throughout the brain and spinal cord. Atalanta is advancing a wholly owned pipeline of disease-modifying programs for Huntington's disease, genetic epilepsy, severe chronic pain, and other neurological diseases in addition to partnered programs as part of a strategic collaboration with Genentech. Atalanta is headquartered in Boston, Mass. For more information, visit
Time of India
28-05-2025
- Business
- Time of India
Confused about college admissions after CET? Find all the answers at the VK Education Fair!
Vijaya Karnataka VK Education Fair 2025 Bangalore University Karnataka Examinations Authority KEA Education Fair The wait is over — the results of the Common Entrance Test (CET) for professional courses have been declared. Now comes the most crucial step: choosing the right course and college. For students and parents alike, this phase often brings confusion, questions, and worry not! To help students make informed choices,is organising the, a two-day mega expo on May 31 and June 1 at the Jnana Jyothi Auditorium,, Central College Campus, Palace VK Education Fair, organised by Vijaya Karnataka, brings together an unmatched educational experience under one roof, offering students and parents all the tools needed to make informed choices than 35 reputed engineering and medical institutions from across Karnataka will participate in the fair, showcasing their courses, fee structures, scholarships, campus facilities, and placement records. This provides a golden opportunity for students to explore a wide range of options directly from the makes this fair even more significant is the presence of officials from the). They will offer detailed explanations about the choice filling process, seat allotment methods, step-by-step counselling procedures, and how to differentiate between government and management quota seats. Students can clear any lingering doubts about the CET admission process with authentic, first-hand addition to institutional representatives, experienced career counsellors and education consultants will be available to guide students in selecting the right course based on their individual interests, aptitudes, and the evolving job market. There will also be special sessions highlighting the growing demand for artificial intelligence and other skill-based tech programs. Experts will also offer insights into education loan facilities, especially for students from economically weaker you're inclined towards science, commerce, arts, or looking at cutting-edge technology-driven courses, the VKpromises a comprehensive overview of all academic streams. This all-encompassing platform helps students weigh multiple options and confidently plan their next fair is free for students and parents. It offers one-on-one interactions with top colleges, access to course and admission details, live clarification of CET counselling procedures with KEA officials, and a chance to discover courses with high venue is easily accessible from all parts of the city via buses or metro services. Adequate parking facilities are also available for private today!Don't miss this unique opportunity to explore your future possibilities and set the foundation for a successful academic journey. For more information, call: 99160 79232 / 96869 38983. — Prakash VL
